The 35th CINP World Congress of Neuropsychopharmacology

Presentation information

[CINP2024] Short Communications

CINP2024 » Short Communications

Short Communications 13
Schizophrenia and Pain - Preclinical

Sat. May 25, 2024 10:10 AM - 11:10 AM Room 8 (G405)

Chair: Rachel A. Hill (Monash University)

[SC13-3] A Rho-kinase 2 selective inhibitor KD025 ameliorates schizophrenia-like behaviors in MK-801-treated mice

*Rinako Tanaka1, Yue Liu1, Jingzhu Liao1, Akihiro Mouri2, Taku Nagai3, Toshitaka Nabeshima4, Kozo Kaibuchi5, Daiki Tachibana6, Yohei Kobayashi6, Norio Ozaki7, Hiroyuki Mizoguchi1, Kiyofumi Yamada1,8 (1. Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2. Department of Regulatory Science for Evaluation & Development of Pharmaceuticals & Devices, Fujita Health University Graduate School of Health Science, Toyoake, Japan, 3. Division of Behavioral Neuropharmacology, International Center for Brain Science (ICBS), Fujita Health University, Toyoake, Japan, 4. Laboratory of Health and Medical Science Innovation, Fujita Health University Graduate School of Health Sciences, Toyoake, Japan, 5. Division of Cell Biology, ICBS, Fujita Health University, Toyoake, Japan, 6. Pharmacology Research Unit, Sumitomo Pharma Co., Ltd., Osaka, Japan, 7. Pathophysiology of mental disorders, Nagoya University Graduate School of Medicine, Nagoya, Japan, 8. ICBS, Fujita Health University, Toyoake, Japan)

Keywords:Belumosudil, KD025, Rho-kinase, schizophrenia, MK-801

Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.

Password